|Trade names||Gattex, Revestive, others|
|Drug class||Glucagon-like peptide-2 (GLP-2)|
|Main uses||Short bowel syndrome|
|Side effects||Abdominal pain, nausea, fluid overload, allergic reactions, headache|
|Typical dose||0.05mg/kg OD|
|Elimination half-life||2 h|
|Chemical and physical data|
|Molar mass||3752.13 g·mol−1|
|3D model (JSmol)|
Teduglutide, sold under the brand names Gattex among others is a medication used for short bowel syndrome. Specifically it is used for people who require parenteral nutrition. It is given by injection just under the skin.
Common side effects include abdominal pain, nausea, fluid overload, allergic reactions, and headache. Other potential side effects may include tumors, intestinal obstruction, gall bladder disease, and pancreatitis. Use during pregnancy appears to be safe. It is similar to the bodies own glucagon-like peptide-2 (GLP-2), which increases the uptake of nutrients from the intestines.
Teduglutide was approved for medical use in the United States and Europe in 2012. At a dose of 5 mg per day, in the United Kingdom it costs the NHS about £15,000 a month as of 2021. This amount in the United States costs about 36,000 per month.
Up to a certain point, the gut can adapt to partial resections that result in short bowel syndrome. Still, parenteral substitution of water, minerals and vitamins (depending on which part of the gut has been removed) is often necessary. Teduglutide may reduce or shorten the necessity of such infusions by improving the intestinal mucosa and possibly by other mechanisms.
Mechanism of action
Teduglutide differs from natural GLP-2 by a single amino acid: an alanine is replaced with a glycine. This blocks breaking down of the molecule by dipeptidyl peptidase and increases its half-life from seven minutes (GLP-2) to about two hours, while retaining its biological actions. These include maintenance of the intestinal mucosa, increasing intestinal blood flow, reducing gastrointestinal motility and secretion of gastric acid.
- "Teduglutide Monograph for Professionals". Drugs.com. Retrieved 24 September 2021.
- "Teduglutide (Gattex) Use During Pregnancy". Drugs.com. Retrieved 24 September 2021.
- "Revestive". Retrieved 24 September 2021.
- BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 54. ISBN 978-0-85711-369-6.CS1 maint: date format (link)
- "Specialty drug prices soaring past six figures per year". KSAT. 26 July 2019. Retrieved 24 September 2021.
- Klement A (5 January 2015). "Das Kurzdarmsyndrom ist erstmals behandelbar: Revestive". Österreichische Apothekerzeitung (in German) (1/2015): 20f.CS1 maint: unrecognized language (link)